Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Neoplasm, Residual 1Mesothelioma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Leukemia, Hairy Cell 1Leukemia 1Epstein-Barr Virus Infections 1Carcinoma, Transitional Cell 1

Interventions

Cytarabine 48Cyclophosphamide 41Etoposide 34fludarabine phosphate 26Filgrastim 26Peripheral Blood Stem Cell Transplantation 25Radiotherapy 24Daunorubicin 24Vincristine 20Methotrexate 20Busulfan 18Mitoxantrone 15Idarubicin 15Doxorubicin 13Dexamethasone 13Rituximab 12Asparaginase 12Prednisone 11Mercaptopurine 11Cyclosporine 11Thioguanine 9Leucovorin 9Ifosfamide 9Antilymphocyte Serum 9laromustine 8Prednisolone 8fludarabine 7Methylprednisolone 7Interferon-alpha 7aldesleukin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia × Caves × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡